INTRODUCTION {#sec1-1}
============

Axillary node status is a powerful predictor of long-term survival in patients with breast cancer and continues to have an important influence on clinical management.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6]\] Sentinel lymph node (SLN) biopsy (SLNB) has demonstrated accuracy in the axillary staging of breast cancer patients,\[[@ref7]\] has low morbidity, and increasingly reflects standard practice among Australian and New Zealand surgeons.\[[@ref8]\]

A number of studies have demonstrated that a combination of radiolocalization with lymphoscintigraphy (LSG) and blue dye mapping increases the success of SLN identification.\[[@ref9][@ref10][@ref11][@ref12]\] The added value of blue dye has been shown to be particularly useful for patients with positive preoperative LSG, having received neoadjuvant chemotherapy, or undergoing superficial injection of tracer agents.\[[@ref4]\]

Radiotracer application itself may be via a number of injection methods, with intradermal (ID), subcutaneous (SC), periareolar (PA), and peritumoral (PT) injection techniques being variously described in the literature.\[[@ref13]\] These techniques each have their own strengths, pitfalls, and advocates. Deep PT injection of radiotracer is required if internal mammary (IM) drainage is to be reliably identified;\[[@ref14][@ref15]\] however, this technique also results in significantly reduced axillary SLN detection when compared with superficial injection techniques.\[[@ref16][@ref17]\] PT injection of upper outer quadrant cancers may also result in the phenomena of "shine through," where the proximity of radiotracer application to an axillary SLN obscures successful identification. In addition to improved detection rates, SC and PA injection sites result in faster axillary SLN visualization and therefore represent the methods of choice if the surgeon wishes to perform LSG intraoperatively.\[[@ref18]\] Some investigators have recommended dual injection with PT and ID radioisotope.\[[@ref19][@ref20]\]

Despite controversy regarding the optimal method of injection, studies have generally suggested a high concordance among the different techniques of radiotracer application and axillary SLN identification.\[[@ref21][@ref22][@ref23]\] This observation has been articulated as the "all roads lead to Rome" model, whereby distinct injection sites will nonetheless drain to the same axillary SLN. Although we know that both superficial and deep injections of radioactive tracer and blue dye are effective for axillary SLN identification, the clinical consequences of discordance rates between the two injection techniques are less clear. Deep injections are associated with greater extra-axillary identification; however, this may not have a significant impact on clinical management.\[[@ref24]\]

Here, we describe a retrospective assessment of a novel LSG technique, where the patients were simultaneously injected with radioisotope in the PT, SC, and SA regions. The aim of this study was to assess the LSG drainage patterns with a view to assessing injection site concordance and SLN identification rates. Discordant SLN identification would have implications for nodal staging as it suggests that the true sentinel node might not be identified with individual injection techniques.

METHODS {#sec1-2}
=======

Patients {#sec2-1}
--------

Imaging from 123 consecutive patients who presented for breast LSG over a 20-month period was retrospectively reviewed. The median patient age was 54 years (range 26--88 years). Invasive ductal carcinoma was the primary breast lesion in 72.4% of patients. The median tumor size was 16 mm (range 1.5--120 mm), and the majority of patients had no previous ipsilateral breast surgery at the time of presentation (85.4%). Other patient characteristics are shown in [Table 1](#T1){ref-type="table"}. All surgical and pathological reports were retrospectively reviewed. Methylene blue dye injection was used in all cases.

###### 

Patient characteristics

  Factor                         *n*(%)
  ------------------------------ ------------
  Number of patients             123
  Sex, female, *n* (%)           122 (99.2)
  Age (years), median±SD         54±11.4
  Tumor size (mm), median±SD     16±17.4
  Histologic findings, *n* (%)   
   IDC                           89 (72.4)
   ILC                           8 (6.5)
   Colloid                       4 (3.3)
   DCIS                          11 (8.9)
   Other carcinoma^†^            8 (6.5)
   No malignancy, no DCIS        3 (2.4)
  Positive SLNB, *n* (%)         27 (22.0)
  Previous surgery, *n* (%)      
   Lumpectomy                    16 (13.0)
   Mastectomy                    0
   Other^‡^                      2 (1.6)
   Nil                           105 (85.4)

^†^Tubular (4), papillary (1), medullary (1), metaplastic (1), apocrine (1); ^‡^Reduction mammoplasty (1), augmentation mammoplasty (1). IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; DCIS: Ductal carcinoma *in situ*; SLNB: Sentinel lymph node biopsy; SD: Standard deviation

Lymphoscintigraphy technique {#sec2-2}
----------------------------

Patients who presented for breast LSG were administered four 10 MBq (same day) or 40 MBq (next day) injections of Tc-99 m antimony sulfide colloid in 0.7 mL (Lymph-Flo, RAH Radiopharmacy North Terrace, Adelaide). Each patient was injected into the PT region, the SC region overlying the tumor, and the SA region in the quadrant of the tumor. Following injection, the patient was instructed to perform gentle massage of the breast for 15 min unless there was a localizing wire *in situ*. Initial image acquisition commenced at 15 min with a Philips BrightView single-photon emission computed tomography (CT)/CT dual-head gamma camera and a low energy high-resolution collimator. High-resolution images were obtained with a 256 × 256 matrix size. Sentinel node location was marked on the skin with indelible ink with the guidance of a Co-57 marker pen. Following LSG, the patients proceeded to surgery either on the same day (71%) or the following day (29%).

Analysis {#sec2-3}
--------

For all 123 patients, the scintigraphic images were retrospectively evaluated with a view to assessing axillary sentinel node drainage patterns. The evaluation was performed by one nuclear medicine physician and one trainee. Where there were differences of opinion, a consensus was reached. All data tabulation and statistical analysis were performed using SPSS 22.0 (IBM, Armonk, NY, USA).

RESULTS {#sec1-3}
=======

Data from 123 breast LSG patients were reviewed. The axillary SLN identification rate, defined as the number of patients in whom an axillary SLN was found divided by the number of patients in whom LSG was performed, was 98% \[[Table 2](#T2){ref-type="table"}\]. No axillary SLN was identified in three patients. In two of these cases, no nodal drainage was identified in any region. In another case, nodal drainage was identified in the IM chain only. Two of three patients without axillary drainage had undergone previous breast surgery: lumpectomy with SLNB in one case and reduction mammoplasty in another. Blue dye was injected intraoperatively in each of these cases, two of which had colored sentinel nodes biopsied and the third had a local wide excision only and no SLNB.

###### 

Nodal identification rates among 123 lymphoscintigraphy patients injected in the peritumoral, subcutaneous, and subareolar regions

  Detected SLNs                     *n*(%)
  --------------------------------- ------------
  Axillary SLNs detected, *n* (%)   
   0                                3 (2.4)
   1                                110 (89.4)
   2                                10 (8.1)
  IM nodes detected, *n* (%)        16 (13.0)

SLNs: Sentinel lymph nodes; IM: Internal mammary

Of the 120 patients with axillary SLN drainage, a single axillary node was detected in 110 patients. Two axillary nodes were detected in 10 cases \[[Table 2](#T2){ref-type="table"}\]. Of the 110 patients with only a single axillary SLN, a single lymphatic channel was identified in 98 patients whereas multiple lymphatic channels were identified in 12 patients. In the majority of cases, it was not possible to correlate individual injection sites with different drainage patterns among these patients with multiple axillary lymphatic channels. However, in two cases, we were able to clearly identify the individual lymphatic channels from separate injection sites converging on a single axillary SLN \[[Figure 1](#F1){ref-type="fig"}\]. This result supports the previous findings that suggest the different injection sites be generally concordant.

![Anterior projection demonstrating separate lymphatic channels from different injection sites draining to the same right axillary sentinel lymph node](WJNM-18-127-g001){#F1}

In contrast to this, of those 10 patients in whom two axillary nodes were detected, discordant drainage was identified in two. In each of these two cases, it was possible to observe separate lymphatic channels from distinct injection sites, each draining to a different (discordant) axillary SLN \[[Figure 2](#F2){ref-type="fig"}\]. In another four cases, separate channels were observed draining to each axillary SLN, but it was unclear whether drainage originated from the same or different injection sites. In another four cases, discrete lymphatic channels were not observed leading to either node.

![Left anterior oblique projection demonstrating discordant left axillary sentinel nodes draining from two different injection sites via different channels](WJNM-18-127-g002){#F2}

DISCUSSION {#sec1-4}
==========

Axillary node status remains an important factor in determining the prognosis and management of patients with breast cancer.\[[@ref5][@ref6]\] Accurate axillary staging is therefore of critical importance. SLNB has been widely adopted by Australian and New Zealand surgeons,\[[@ref4][@ref8]\] and radiolocalization with LSG in combination with blue dye mapping remains the optimal method in SLN identification.\[[@ref10]\]

In this study, we describe the results of a novel radiotracer application method, whereby the patients were simultaneously injected with radioisotope in the PT, SC, and SA regions. This technique was used to cover all drainage pathways. The axillary SLN localization rate for our LSG technique was found to be 98%, which lies at the upper limit of reported LSG detection rates (approximately 74%--98%).\[[@ref17][@ref25][@ref26]\]

As well as the application technique, a number of other factors influence LSG axillary SLN detection rates. These include previous breast surgery, older patient age, increased BMI, and tumor grade.\[[@ref27][@ref28][@ref29][@ref30]\] Interestingly, in our sample of three patients in whom axillary SLN detection was not possible, two of them reported previous breast surgery. One of these patients had undergone previous lumpectomy and SLNB, while the other had undergone reduction mammoplasty. This raises the possibility that nondetection in these patients may have been related to prior breast surgery although there are currently little published data regarding the impact of aesthetic breast surgery on axillary SLN detection rates. One study of 20 patients who underwent breast reduction mammoplasty did not find any corresponding change in LSG detection rates.\[[@ref31]\]

Prior studies have shown that differing SLN techniques can identify nonaxillary nodes in up to 43% of patients depending on the type and volume of tracer, injection technique, and primary tumor location and size.\[[@ref32][@ref33]\] In addition to superior or equivalent rates of axillary SLN, our method of radiotracer application also enabled detection of IM lymph nodes. This is in contrast to the SC and PA techniques where IM drainage is not reliably demonstrated.\[[@ref15][@ref16]\] IM drainage has prognostic significance for patients with positive axillary SLN results,\[[@ref34]\] and if IM radiotherapy is to be considered, deep injection techniques are required. In our series, 13% of the patients demonstrated IM drainage \[[Table 2](#T2){ref-type="table"}\], similar to the previous findings.\[[@ref35]\]

Published studies overall have suggested very high concordance between the different techniques of radiotracer application.\[[@ref22][@ref23][@ref24]\] The anatomic basis for this appears to be the presence of several lymphatic channels converging on the same axillary SLN. This has been articulated as the "all roads lead to Rome" model. There have been some conflicting results, however\[[@ref34][@ref36]\] highlighting the importance of further study. Our results have shown examples of different injection sites, leading to the same axillary SLN via different sentinel channels, in accordance with the "all roads lead to Rome" hypothesis \[[Figure 1](#F1){ref-type="fig"}\]. It remains important for those involved in SLNB to be aware of the different drainage patterns of superficial and deep injections which are both covered in our injection technique.\[[@ref37]\]

In performing a retrospective analysis of breast LSG using our injection technique, we were able to qualitatively assess drainage pathway discordance. In this context, we defined discordance as occurring when different injection sites led to the identification of a different axillary SLN. In two cases, we were able to directly observe discordant axillary SLN drainage via different injection site techniques \[[Figure 2](#F2){ref-type="fig"}\]. Identification of such SLN discordance with the different injection sites has implications for nodal staging if the "true" SLN is not identified with a particular injection technique. As stated previously, the two patients with discordant drain-age each received two PT, one SC, and one SA injections of tracer.

This study has a number of limitations. Due to its retrospective observational nature, we were unable to directly compare our high multisite technique detection rates with single-injection techniques. The staff in our Department have considerable experience with breast LSG which may partly account for the high detection rate seen. Indeed, operator inexperience has a known association with lower SLN detection rates.\[[@ref38]\] Second, the false-negative rate in our sample was unable to be calculated. Whether our radiotracer application technique resulted in fewer non-SLN discoveries of metastatic disease remains unknown.

CONCLUSION {#sec1-5}
==========

We have demonstrated that different LSG injection sites can lead to the identification of different axillary sentinel nodes. This finding may be of clinical importance if the "true" SLN is to be sought with LSG. We have also described a novel triple-site technique of radiotracer application in breast LSG. This technique was associated with a high axillary SLN detection rate and allowed identification of IM drainage. In view of these findings, our triple-site injection technique appears to be a good method, with further investigation required, of axillary SLN detection. However, if two (or more) sentinel nodes are identified using this technique, they both require pathological assessment for accurate staging.
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